If a new race-free equation for assessing chronic kidney disease is widely adopted in the US, this will potentially impact medication dosing, insurance coverage, and kidney transplant eligibility.
Prospectively collected data from 4314 South Korean adults showed that people with higher levels of insulin resistance have the greatest rate of incident type 2 diabetes and chronic kidney disease.
The US FDA gave accelerated approval to sparsentan as the first non-immunosuppressive therapy labeled for IgA nephropathy. Conventional approval awaits clinical outcomes data.
The US Food and Drug Administration has approved daprodustat as oral treatment for anemia in patients with chronic kidney disease and on dialysis, but not for patients who are not on dialysis.